Omakase Consulting has participated in a meeting to present the Roadmap in immunotherapy applied to oncology (Horizon 2022) to Patricia Lacruz and other members from her team in the General Direction of Pharmacy (DGF) of the Spanish Ministry of Health.

//Omakase Consulting has participated in a meeting to present the Roadmap in immunotherapy applied to oncology (Horizon 2022) to Patricia Lacruz and other members from her team in the General Direction of Pharmacy (DGF) of the Spanish Ministry of Health.

Omakase Consulting has participated in a meeting to present the Roadmap in immunotherapy applied to oncology (Horizon 2022) to Patricia Lacruz and other members from her team in the General Direction of Pharmacy (DGF) of the Spanish Ministry of Health.

Omakase Consulting has participated in a meeting to present the Roadmap in immunotherapy applied to oncology (Horizon 2022) to Patricia Lacruz and other members from her team in the General Direction of Pharmacy (DGF) of the Spanish Ministry of Health. This has been an initiative of ECO Foundation coordinated by Omakase Consulting and supported by Roche

The vision and impact of the proposed lines of work have been presented by presidents and representatives of SEOM, ECO, SEEO, SEFH, GEPAC and Spanish Patients’ Forum in a multidisciplinary exercise that incorporates the perspectives of the main agents involved in the oncological area of our country. The DGF has recognized the value of the initiative and congratulated the working group, recognizing the transversality and alignment of the Roadmap with the current lines of work coordinated by the Ministry in the current framework of review of the National Strategy on Cancer of the NHS. Both parties are committed to work together towards the common goal of adequately reflecting the challenges and opportunities associated with immunotherapy in this strategy, contributing to improving the health outcomes of cancer patients.

—————-

Omakase Consulting ha participado hoy en una reunión para la presentación de la propuesta de una Hoja de Ruta en Inmunoterapia aplicada a Oncología (Horizonte 2022) a Patricia Lacruz y miembros de su equipo en la Dirección General de Farmacia del Ministerio de Sanidad, una iniciativa de la Fundación ECO coordinada por Omakase Consulting y con el apoyo de Roche
La visión y el impacto de las líneas de trabajo propuestas han sido presentadas por presidentes y representantes de SEOM, ECO, SEEO, SEFH, GEPAC y Foro Español de Pacientes en un ejercicio multidisciplinar que incorpora las perspectivas de los principales agentes involucrados en el área oncológica de nuestro país. La DGF ha reconocido el valor de la iniciativa y felicitado al grupo de trabajo, reconociendo la transversalidad y alineamiento de la Hoja de Ruta con las líneas de trabajo actuales coordinadas por el Ministerio en el marco actual de revisión de la Estrategia Nacional en Cáncer del SNS. Ambas partes se han emplazando a trabajar de manera conjunta en el objetivo común de reflejar de manera adecuada los retos y oportunidades asociados a la inmunoterapia a dicha estrategia, contribuyendo a mejorar los resultados en salud de los pacientes oncológicos.
2020-10-07T09:22:51+00:00October 6th, 2020|News & Events|

Leave A Comment

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies